SAB-142

Product

Last mentioned: Mar 17, 2026

Timeline

Mar 17, 2026
Wall Street Zen Downgrade

SABS and SSSS both receive Sell ratings from Wall Street Zen.
Q4 2025
SAB-142 Clinical Progress

SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
2025
Strategic Pivot

Company shifts focus from infectious diseases to immunology and chronic conditions.

Stories mentioning SAB-142 1

pharma Neutral

SAB Biotherapeutics Downgraded to Sell Amid Shifting Biotech Sentiment

Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.

Mar 17, 2026 2 sources